Key statistics
As of last trade Axsome Therapeutics Inc (19X:DUS) traded at 93.88, -3.73% below its 52-week high of 97.52, set on Nov 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 93.04 |
---|---|
High | 93.88 |
Low | 92.98 |
Bid | 93.96 |
Offer | 95.56 |
Previous close | 92.30 |
Average volume | 293.11 |
---|---|
Shares outstanding | 48.00m |
Free float | 39.17m |
P/E (TTM) | -- |
Market cap | 4.71bn USD |
EPS (TTM) | -6.54 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 11:30 GMT.
More ▼
Announcements
- Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
- Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
- Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
- Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
- Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
- Axsome Therapeutics to Participate in Investor Conferences in September
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
More ▼